Patent ID: 11970535
Assignee: INNATE PHARMA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating a T cell malignancy with tissue manifestation, the method comprising administering to an individual having a T cell malignancy an agent that binds a KIR3DL2 polypeptide and is capable of causing effector cell-mediated lysis of a KIR3DL2-expressing cell, for at least one administration cycle in which the agent is administered at least twice in an amount that maintains a concentration in blood of at least the EC60 for NK lytic capacity, between two successive administrations of the agent, wherein the agent is an antibody that binds specifically to a KIR3DL2 polypeptide and is administered in an amount of 10 mg/kg body weight or as a fixed dose equivalent of 750 mg, and wherein the treatment regimen comprises:
an induction period in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of one administration per week, and
a treatment period in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of one or two administrations per month, and
wherein the agent is an antibody comprising: a heavy chain CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising SEQ ID NO: 2 (HCDR1), SEQ ID NO: 3 (HCDR2) and SEQ ID NO: 4 (HCDR3) respectively, and a light chain CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising SEQ ID NO: 5 (LCDR1), 6 (LCDR2) and 7 (LCDR3) respectively; or
a heavy chain CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising SEQ ID NO: 18 (HCDR1), SEQ ID NO: 19 (HCDR2) and SEQ ID NO: 20 (HCDR3) respectively, and a light chain CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising SEQ ID NO: 21 (LCDR1), 22 (LCDR2) or 23 (LCDR3).